語系:
繁體中文
English
說明(常見問題)
圖資館首頁
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Prehypertension and cardiometabolic ...
~
Julius, Stevo.
Prehypertension and cardiometabolic syndrome
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Prehypertension and cardiometabolic syndromeedited by Reuven Zimlichman, Stevo Julius, Giuseppe Mancia.
其他作者:
Zimlichman, Reuven.
出版者:
Cham :Springer International Publishing :2019.
面頁冊數:
xii, 689 p. :ill., digital ;24 cm.
Contained By:
Springer eBooks
標題:
Hypertension.
電子資源:
https://doi.org/10.1007/978-3-319-75310-2
ISBN:
9783319753102$q(electronic bk.)
Prehypertension and cardiometabolic syndrome
Prehypertension and cardiometabolic syndrome
[electronic resource] /edited by Reuven Zimlichman, Stevo Julius, Giuseppe Mancia. - Cham :Springer International Publishing :2019. - xii, 689 p. :ill., digital ;24 cm. - Updates in hypertension and cardiovascular protection,2366-4606. - Updates in hypertension and cardiovascular protection..
I Epidemiology and Statistics -- 1 Epidemiology, statistics and health burden -- 2 PreHypertension, the risk of Hypertension and events -- 3 Parental history of hypertension as the determinant of cardiovascular function -- 4 High normal blood pressure in children and adolescents -- II Pathophysiology of prehypertension.- Part 1 Alteration of Cardiovascular control systems -- 5 Tachycardia in PreHypertension -- 6 Endothelial dysfunction in early phases of hypertension -- 7 Prehypertension and the Renin angiotensin aldosterone system -- 8 The role of the brain in neurogenic prehypertension -- 9 The blood pressure seeking property of the brain -- Part 2 Organ damage in Prehypertension -- 10 Microvascular structural alternations and tissue perfusion in hypertension and diabetes -- 11 The heart in prehypertension -- 12 The role of the kidney in PreHypertension -- 13 Obesity, Hypertension and Chronic Kidney Disease: A Forty Year Retrospective -- 14 Pre-CKD? Early markers of renal dysfunction in patients with Prehypertension -- 15 Arterial stiffness in early phases of Prehypertension -- 16 The role of perivascular fat in raising blood pressure in obesity and diabetes -- 17 The Brain -- 18 Diurnal and pulsatile hemodynamics in individuals with PreHypertension -- 19 Systolic hypertension in youth -- 20 Prehypertension and ethnicity: Haemodynamic mechanisms in young adults -- 21 Hemodynamics (systemic and renal) in prehypertension -- 22 Central blood pressure and Prehypertension -- Section 3: Risk assessment in PreHypertension -- 23 Blood pressure measurement, white coat and masked hypertension -- 24 Vascular functional and structural risk assessment in prehypertension -- 25 Blood pressure variability -- 26 Morning Surge of Blood Pressure -- 27 Role of ambulatory Blood Pressure Monitoring in Prehypertension -- 28 Home blood pressure, prehypertension and hypertension -- 29 Blood pressure and atherosclerosis- subclinical arteriosclerosis as an early sign of organ damage -- 30 Response to stress, effort and cold pressor test as predictors of Prehypertension -- 31 Physical Activity and Exercise Training as Important Modifiers of Vascular Health -- 32 Prehypertension and associated metabolic risk factors -- IV End organ damage in PreHypertension -- 33 Early cardiovascular dysfunction in Prehypertension -- 34 Effect of blood pressure lowering in hypertensive rats -- V Clinical studies in PreHypertension -- 35 Review of "old and new studies" in the treatment of PreHypertension -- 36 The CHINON study- argument for early treatment of PreHypertension. Effect of age on progression of hypertension -- 37 The PREVER study -- 38 The TROPHY study -- VI Management of PreHypertension -- 39 Non-pharmacologic approaches for the management of prehypertension -- 40 Antihypertensive drugs and vascular health -- 41 Prehypertension: a case in favor of early use of diuretics -- 42 Treatment of High normal blood pressure in the guidelines -- VII Tentative additional chapters -- 43 History of prehypertension: a saga of misunderstanding and neglect -- 44 Management of Prehypertension and hypertension in women of reproductive age.
This book sheds new light on the management of patients with borderline cardiovascular risk factors in order to prevent their progression to end organ damage. The book stimulates discussion of this poorly understood condition and lays the groundwork for developing recommendations and guidelines. While the diagnostic and therapeutic approach to full-blown diabetes, hypertension, dyslipidemia and obesity is well defined, there is still a lack of clear understanding and guidelines as far as patients with borderline conditions - especially when multiple - are concerned. Moreover, end-organ damage depends on several factors, including genetic factors, making it difficult to predict its extent. As such, the gradual transition from a healthy subject to one with functional hemodynamic changes, and then one with structurally asymptomatic changes and lastly to overt disease needs further investigation. In order to address these knowledge gaps, the book covers a broad variety of topics, making it a valuable tool for identifying which asymptomatic subjects could profit from being appropriately screened and at what stage. Furthermore it offers insights into better treating these patients to prevent their progression to overt disease. The book appeals to cardiologists, primary care physicians and all those healthcare professional looking to optimize the management of these complex and often undiagnosed cases.
ISBN: 9783319753102$q(electronic bk.)
Standard No.: 10.1007/978-3-319-75310-2doiSubjects--Topical Terms:
200895
Hypertension.
LC Class. No.: RC685.H8 / P744 2019
Dewey Class. No.: 616.132
Prehypertension and cardiometabolic syndrome
LDR
:05636nmm a2200337 a 4500
001
555834
003
DE-He213
005
20190712113936.0
006
m d
007
cr nn 008maaau
008
191121s2019 gw s 0 eng d
020
$a
9783319753102$q(electronic bk.)
020
$a
9783319753096$q(paper)
024
7
$a
10.1007/978-3-319-75310-2
$2
doi
035
$a
978-3-319-75310-2
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC685.H8
$b
P744 2019
072
7
$a
MJD
$2
bicssc
072
7
$a
MED010000
$2
bisacsh
072
7
$a
MJD
$2
thema
082
0 4
$a
616.132
$2
23
090
$a
RC685.H8
$b
P923 2019
245
0 0
$a
Prehypertension and cardiometabolic syndrome
$h
[electronic resource] /
$c
edited by Reuven Zimlichman, Stevo Julius, Giuseppe Mancia.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2019.
300
$a
xii, 689 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
Updates in hypertension and cardiovascular protection,
$x
2366-4606
505
0
$a
I Epidemiology and Statistics -- 1 Epidemiology, statistics and health burden -- 2 PreHypertension, the risk of Hypertension and events -- 3 Parental history of hypertension as the determinant of cardiovascular function -- 4 High normal blood pressure in children and adolescents -- II Pathophysiology of prehypertension.- Part 1 Alteration of Cardiovascular control systems -- 5 Tachycardia in PreHypertension -- 6 Endothelial dysfunction in early phases of hypertension -- 7 Prehypertension and the Renin angiotensin aldosterone system -- 8 The role of the brain in neurogenic prehypertension -- 9 The blood pressure seeking property of the brain -- Part 2 Organ damage in Prehypertension -- 10 Microvascular structural alternations and tissue perfusion in hypertension and diabetes -- 11 The heart in prehypertension -- 12 The role of the kidney in PreHypertension -- 13 Obesity, Hypertension and Chronic Kidney Disease: A Forty Year Retrospective -- 14 Pre-CKD? Early markers of renal dysfunction in patients with Prehypertension -- 15 Arterial stiffness in early phases of Prehypertension -- 16 The role of perivascular fat in raising blood pressure in obesity and diabetes -- 17 The Brain -- 18 Diurnal and pulsatile hemodynamics in individuals with PreHypertension -- 19 Systolic hypertension in youth -- 20 Prehypertension and ethnicity: Haemodynamic mechanisms in young adults -- 21 Hemodynamics (systemic and renal) in prehypertension -- 22 Central blood pressure and Prehypertension -- Section 3: Risk assessment in PreHypertension -- 23 Blood pressure measurement, white coat and masked hypertension -- 24 Vascular functional and structural risk assessment in prehypertension -- 25 Blood pressure variability -- 26 Morning Surge of Blood Pressure -- 27 Role of ambulatory Blood Pressure Monitoring in Prehypertension -- 28 Home blood pressure, prehypertension and hypertension -- 29 Blood pressure and atherosclerosis- subclinical arteriosclerosis as an early sign of organ damage -- 30 Response to stress, effort and cold pressor test as predictors of Prehypertension -- 31 Physical Activity and Exercise Training as Important Modifiers of Vascular Health -- 32 Prehypertension and associated metabolic risk factors -- IV End organ damage in PreHypertension -- 33 Early cardiovascular dysfunction in Prehypertension -- 34 Effect of blood pressure lowering in hypertensive rats -- V Clinical studies in PreHypertension -- 35 Review of "old and new studies" in the treatment of PreHypertension -- 36 The CHINON study- argument for early treatment of PreHypertension. Effect of age on progression of hypertension -- 37 The PREVER study -- 38 The TROPHY study -- VI Management of PreHypertension -- 39 Non-pharmacologic approaches for the management of prehypertension -- 40 Antihypertensive drugs and vascular health -- 41 Prehypertension: a case in favor of early use of diuretics -- 42 Treatment of High normal blood pressure in the guidelines -- VII Tentative additional chapters -- 43 History of prehypertension: a saga of misunderstanding and neglect -- 44 Management of Prehypertension and hypertension in women of reproductive age.
520
$a
This book sheds new light on the management of patients with borderline cardiovascular risk factors in order to prevent their progression to end organ damage. The book stimulates discussion of this poorly understood condition and lays the groundwork for developing recommendations and guidelines. While the diagnostic and therapeutic approach to full-blown diabetes, hypertension, dyslipidemia and obesity is well defined, there is still a lack of clear understanding and guidelines as far as patients with borderline conditions - especially when multiple - are concerned. Moreover, end-organ damage depends on several factors, including genetic factors, making it difficult to predict its extent. As such, the gradual transition from a healthy subject to one with functional hemodynamic changes, and then one with structurally asymptomatic changes and lastly to overt disease needs further investigation. In order to address these knowledge gaps, the book covers a broad variety of topics, making it a valuable tool for identifying which asymptomatic subjects could profit from being appropriately screened and at what stage. Furthermore it offers insights into better treating these patients to prevent their progression to overt disease. The book appeals to cardiologists, primary care physicians and all those healthcare professional looking to optimize the management of these complex and often undiagnosed cases.
650
0
$a
Hypertension.
$3
200895
650
1 4
$a
Cardiology.
$3
273804
650
2 4
$a
Angiology.
$3
275861
650
2 4
$a
Diabetes.
$3
274215
650
2 4
$a
Metabolic Diseases.
$3
274217
650
2 4
$a
Primary Care Medicine.
$3
275823
700
1
$a
Zimlichman, Reuven.
$3
838145
700
1
$a
Julius, Stevo.
$3
838146
700
1
$a
Mancia, Giuseppe.
$3
493827
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer eBooks
830
0
$a
Updates in hypertension and cardiovascular protection.
$3
750391
856
4 0
$u
https://doi.org/10.1007/978-3-319-75310-2
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
全部
電子館藏
館藏
1 筆 • 頁數 1 •
1
條碼號
館藏地
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
000000168646
電子館藏
1圖書
電子書
EB RC685.H8 P923 2019 2019
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
多媒體檔案
https://doi.org/10.1007/978-3-319-75310-2
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入